Implications of RNA virus persistence for post-acute sequelae and chronic inflammatory syndromes.

Publication date: Aug 01, 2026

Viral persistence refers to the ability of a virus to remain in its host for an extended period. Although most non-retroviral RNA viruses are traditionally known for causing acute, self-limiting infections, accumulating evidence of the detection of viral products long after the infectious virus is cleared suggests that RNA viruses can establish persistent infections. Persistent viral products include replication-competent viral genomes, viral proteins, mutated viruses or non-standard viral genomes. The persistence of viral products entails a continuous interaction with the host and is often associated with prolonged tissue inflammation and chronic disease. Here, we discuss emerging evidence of the persistence of viral products from viruses commonly considered to cause acute infections. We explore the known requirements for virus persistence and the implications for the development of post-acute sequelae and predisposition to chronic inflammatory syndromes.

Open Access PDF

Concepts Keywords
Genomes Animals
Inflammation Chronic Disease
Proteins Genome, Viral
Traditionally Host-Pathogen Interactions
Viruses Humans
Inflammation
Persistent Infection
Post-Acute COVID-19 Syndrome
RNA Virus Infections
RNA Viruses
Virus Replication

Semantics

Type Source Name
disease MESH syndromes
disease MESH infections
disease MESH persistent infections
disease MESH inflammation
disease MESH chronic disease
disease MESH influenza
disease MESH parainfluenza
disease MESH measles
pathway KEGG Measles
disease MESH hepatitis
disease MESH subacute sclerosing panencephalitis
disease MESH SARS CoV 2 infection
drug DRUGBANK Trestolone
drug DRUGBANK Cycloserine
disease MESH DCs
disease MESH Infectious Diseases
disease MESH mumps
pathway KEGG Viral replication
disease MESH face
disease MESH reinfection
drug DRUGBANK Tretamine
disease MESH virus infections
pathway REACTOME Release
disease MESH death
disease MESH Zika virus infection
disease MESH long COVID
disease MESH Cardiomyopathies
disease MESH amnesia
disease MESH fatigue
disease MESH cognitive dysfunction
disease MESH smell dysfunction
disease MESH abdominal pain
disease MESH nausea
pathway REACTOME Immune System
disease MESH uveitis
disease MESH chronic fatigue syndrome
disease MESH arthralgia
disease MESH asthma
pathway KEGG Asthma
disease MESH brain fog
disease MESH Lightheadedness
disease MESH dementia
disease MESH lethargy
disease MESH generalized seizures
disease MESH epilepsy
disease MESH myoclonus
disease MESH involuntary movements
disease MESH headaches
disease MESH dysesthesias
disease MESH mood disorders
disease MESH anxiety
disease MESH cough
disease MESH dyspnea
disease MESH muscle pain
disease MESH rash
disease MESH alopecia
disease MESH hearing loss
disease MESH Musculoskeletal diseases
disease MESH arthritis
disease MESH vasculitis
disease MESH Dis
disease MESH Emergency
drug DRUGBANK Ilex paraguariensis leaf
disease MESH CNS disease
disease MESH chikungunya virus infection
disease MESH Ebola virus disease
disease MESH meningoencephalitis
pathway REACTOME Cholesterol biosynthesis
disease MESH pneumonia
pathway REACTOME Translation
disease MESH strains
disease MESH respiratory syncytial virus infection
disease MESH Ross River virus infection
pathway KEGG Endocytosis
disease MESH recrudescence
disease MESH coxsackievirus infection
disease MESH Enterovirus infections
disease MESH Lassa fever
disease MESH convalescence
disease MESH inflammatory bowel diseases
disease MESH tenosynovitis
disease MESH myositis
disease MESH dilated cardiomyopathy
pathway KEGG Dilated cardiomyopathy
pathway REACTOME Apoptosis
pathway REACTOME Influenza Infection
disease MESH COPD
drug DRUGBANK Sulfasalazine
drug DRUGBANK Coenzyme M
disease MESH RNA Virus Infections

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *